Trial Profile
Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Pancreatitis
- Focus Therapeutic Use
- Acronyms RAPID-I
- 03 May 2023 Status changed from recruiting to completed.
- 02 Sep 2022 The recruitment end date was changed from 30/09/2020 to 30/04/2023.
- 02 Sep 2022 Status changed from completed to recruiting.